This course has expired. View available courses.
Oncology
Clinical Brief Series: Adjuvant immunotherapy for melanoma
Adjuvant immunotherapy has recently become a treatment option for patients with melanoma and sentinel lymph node biopsy (SLNB) plays a critical role in identifying the subset of patients at high risk of recurrence or relapse following complete resection who may benefit.
This 4-part series explores the latest clinical evidence and recommendations for adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma, discusses which patients are appropriate for SLNB, what this procedure involves and how the results of SLNB should guide adjuvant therapy.
It also explores practical aspects of care with a focus on the importance of early identification and contains a case study.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.
DURATION
1h
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-03-18
Adjuvant immunotherapy has recently become a treatment option for patients with melanoma and sentinel lymph node biopsy (SLNB) plays a critical role in identifying the subset of patients at high risk of recurrence or relapse following complete resection who may benefit.
This 4-part series explores the latest clinical evidence and recommendations for adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma, discusses which patients are appropriate for SLNB, what this procedure involves and how the results of SLNB should guide adjuvant therapy.
It also explores practical aspects of care with a focus on the importance of early identification and contains a case study.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.
Faculty
A/Prof Victoria Atkinson,
Medical Oncologist, Senior Staff Specialist, Princess Alexandra Hospital, QLD
Dr Lisa Beecham,
General Practitioner, Robina Town Medical Centre, QLD
Learning objectives
On completion of this program, participants will be able to:
- Recall the latest clinical evidence and recommendations on the role of adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma
- Describe the evidence for initial excisional biopsy removal of possible melanoma lesions
- Describe the role of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of recurrence or relapse following complete resection of melanoma, who may benefit from adjuvant immunotherapy
- Incorporate into current practice a systematic approach for identifying patients with melanoma who should be referred to a surgeon for SLNB
- Outline the ways in which a multidisciplinary team approach can improve outcomes for patients with melanoma
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 227975
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.